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Abstract  
Background 
Good practice guidelines highlight the importance of making people with epilepsy aware of 
the risk of premature mortality in epilepsy particularly due to Sudden Unexpected Death in 
Epilepsy (SUDEP). The SUDEP and Seizure Safety Checklist (“Checklist”) is a structured risk 
communication tool used in UK clinics. It is not known if sharing structured information on 
risk factors allows individuals to reduce SUDEP and premature mortality risks. 
 
Aim 
To ascertain if the introduction of the Checklist in epilepsy clinics lead to individual risk 
reduction 
 
Method –  
The Checklist was administered to 130 consecutive people with epilepsy attending an 
epilepsy specialised neurology clinic and 129 attending an Intellectual Disability epilepsy 
clinic within a 4 month period. At baseline, no attendees at the neurology clinic had 
received formal risk advice while all attending the ID clinic had on multiple occasions for six 
years. A year later the Checklist was re-administered to each group and scores were 
compared with baseline and between groups.  
 
Results –  
Of 12 risk factors considered there was an overall reduction in mean risk score for the 
general population (p=0.0049) but not for the ID population (p=0.322). Sub analysis of 25% 
at most risk of both populations showed both sets had a significant reduction in risk scores 
(p<0.001). 
 
Conclusion - 
Structured discussion results in behavioural change which reduces individual risk factors. 
This impact seems higher in those who are at higher risk currently. It is important clinicians 
share risk information with individuals as a matter of public health and health promotion. 
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Introduction 
People will generally modify behaviour and change lifestyle if they feel that there is an 
advantage or benefit. People need to have a comprehensive understanding of specific risks. 
Health risks are conveyed by clinicians in a myriad of ways of variable quality and 
effectiveness. A host of clinical and individual factors play a role in person-centred 
communication [1]. The lack of a clear structure to capture this quality of communication 
could influence outcomes.  
New guidance from The American Academy of Neurology (AAN) recognises the importance 
of communicating the risk of Sudden Unexpected Death in Epilepsy (SUDEP) to people with 
epilepsy [2] mirroring the  UK’s National Institute of Clinical Excellence (NICE) [3]  epilepsy 
guidance. Both guidelines lack elaboration on how to deliver person centred risk 
assessment. Another concern is epilepsy risk discussion is expected to occur shortly after 
diagnosis. It has, however, been shown in chronic conditions such as epilepsy, that risk can 
change over time and is influenced by varying life factors [4]. People with epilepsy are rarely 
aware of changing risk often to their detriment. Thus what can start as ‘low’ risk can over 
time switch to a ‘higher’ risk without the individual, carers or the clinician being fully aware 
[5].  It is therefore important to update risk assessment and feedback based on the course 
of an individual’s epilepsy and how it may change.  
There are about half a million people with epilepsy in the UK and in 2013, almost 1200 of 
them died as a result of epilepsy, roughly the same number who died from asthma in the 
same year [6]. This is despite the number of people with asthma being 10 times greater [6].   
Over a third of epilepsy deaths could have been avoidable whilst only a quarter of asthma 
deaths were identified as preventable [6].  This suggests that there is significant room for 
improvement in the way risk identification and management of people with epilepsy can be 
delivered. It has been shown that the risk of premature mortality risk in epilepsy is rarely 
practiced due to lack of clarity of what needs to be said [7]. A recent survey suggests that 
many specialists do not discuss SUDEP and that risk discussion is arbitrary led by clinician 
judgment [8]. 
A safety checklist was developed which uses available evidence to determine 19 SUDEP risk 
factors divided into modifiable and non-modifiable risks [9]. These are on seizures, physical 
health, psychological and social issues, thus providing individuals a holistic overview of their 
current situation [9] .  These factors were subsequently examined in those who had died 
from SUDEP (n=48) in the UK county of Cornwall (population 550,000) between 2004 -2012 
compared with people with epilepsy still living [4]. It was found that 17 factors were 
associated with SUDEP and directly relevant for people living with epilepsy [10] 1. These 17 
factors form the background of the Seizure and SUDEP safety checklist (“Checklist”) 
(https://www.sudep.org/checklist), a 10 minute risk communication tool and the self-
monitoring of epilepsy risk mobile app EpSMon [11]. The Checklist considers risk factors 
associated with epilepsy mortality, including but not restricted to SUDEP. The Checklist is 
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provided in appendix 1(supplementary data) and key risk factors and their narrative are 
listed in table 1 (modifiable factors indicated as ‘M’).   
Of the 19 factors in the original Checklist, twelve were considered modifiable [4, 5, 10] and 
seven non-modifiable, focussing clinicians’ discussions with individuals on modifiable 
factors. It can be repeated annually, when risk factors change at follow up or when there is 
a treatment change.   
 
Aim 
We aimed to determine whether the introduction of a risk communication checklist in an 
epilepsy clinic leads to a reduction in individual SUDEP and epilepsy mortality risk factors. 
 
Method 
We used the Checklist prospectively in two sets of specialist secondary care epilepsy clinics 
in Cornwall as part routine clinical practice and audited the findings after two applications 
one year apart. The first was a neurology epilepsy clinic. None of those referred to the 
neurology clinic had previous counselling concerning SUDEP risk. The population in this 
clinic included people with newly diagnosed epilepsy; people with epilepsy re-referred from 
primary care and those with treatment resistant epilepsy on routine follow up.  
The second clinic specialized in epilepsy and intellectual disability (ID) in which discussion of 
SUDEP risk had been the practice since 2010. All attendees have moderate to profound ID 
and thus are in twenty four hour supported care with a designated carer or a family 
member. The administration of the checklist in this group was directly to a family member 
or carer. Where eligible i.e. individual was capable to process risk, feedback was also given 
by an ‘easy read’ format to the individual. Due to previous exposure to discussion of SUDEP 
risk and being in 24/7 supported care environment and having a nominated carer to deliver 
actions this population was considered an appropriate comparison group. One would expect 
that the majority of the modifiable risk factors in this population are better controlled due 
to the level of supervision and monitoring people with ID receive in comparison to the 
general population. All those attending this clinic were recognised to have treatment 
resistant epilepsy on routine 3 monthly follow ups.  
Those with epilepsy attending these clinics between November 2015 and March 2016 were 
counselled on their personal SUDEP and epilepsy risk using the Checklist. The checklist was 
administered by an epilepsy nurse or by a specialist who had training in doing so. No 
baseline comparison between these two populations was done at the start of the project.  
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One year later all underwent the application of the checklist to ascertain if the advice 
provided using the checklist had reduced risk scores. Numbers of those discharged from 
both clinics in the interim one year were excluded. The focus was on the 12 modifiable risks. 
Seizure change was recorded from case notes by using changes in seizure frequency by 
counting seizures reported and recorded at clinic appointments in the interim between the 
applications. ‘Change’ was defined as at least 25% change in frequency constant for at least 
6 months till the re-application of the checklist. 
The demographic characteristics and risk factors were summarized at baseline in both 
populations using percentage frequencies for categorical variables, and means and standard 
deviations for the continuous variables. These summary measures were compared across 
groups to identify baseline differences between the two groups. McNemar’s test was used 
to test where there were changes in individual risk factors from baseline to follow-up in 
each clinic group. The threshold for declaring statistical significance was set at p < 0.05. 
A risk index was created whereby individuals receive a score of 1 for each modifiable risk 
factor and 0 if they do not have the risk factor. The total score is obtained by a simple sum 
of the values from 12 risk factors. The distribution of risk scores was plotted separately at 
baseline and follow-up for each group using boxplots. Differences in the risk scores between 
baseline and follow-up were assessed using paired t-tests.   
To determine if the Checklist had also made a difference in those identified as the most at 
risk, the baseline risk scores were ranked separately in each group and a threshold score 
chosen such that approximately top 25% scored above the threshold were sub analysed and 
compared. This was done by selecting individuals with a baseline risk score of 5 or more in 
each group. Changes in risk scores between baseline and follow-up were compared within 
these high risk sub-groups as above. 
 
As this exercise did not involve treatment changes, interventions or randomization and as the 
Checklist is routinely used it was registered as a service evaluation.   
 
Results 
The checklist was applied to 130 consecutive individuals in the neurology clinic and similarly 
to 129 people in the ID clinic. Demographic and clinical details are provided in table 2.  
During the following year 39 and 36 of the original cohorts were lost to follow up or 
discharged from their respective services thus not available for the second check. Therefore, 
91 individuals were available from the neurology clinic and 93 ID cohorts for the second 
application.    The epilepsy duration at baseline had a broad distribution in the general 
population with 41% having seizures for less than 5 years and 32% having seizures over 15 
years whereas over 90% of the ID population had seizures over 15 years. Twenty eight 
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percent of the general population had generalised seizures as compared to 68% with ID. 
Group differences at baseline were significant for age (p=0.01), number of AEDs (p<0.001), 
seizure duration (p<0.001) and type i.e. generalised epilepsy (y/n; p<0.001) and for alcohol 
abuse (p=0.002). All other group variables (Table 1) were non-significant (p≥0.05). 
Changes to the 12 risk factors individually considered are shown in Tables 3 & 4.  Figure 1 
shows the distribution of risk scores at baseline and follow-up separately for the general 
and the ID populations. There was an overall reduction in mean risk score for the general 
population (p=0.049 paired t-test) but not for the ID population (p=0.322).  Groups 
differences in terms of overall reduction in mean risk score was not significant (p=0.38). Risk 
scores were ranked by selecting the top 25% of each group (table 5). In both cases, there 
was a statistically significant mean reduction in risk score (p<0.001). End analysis of the sub -
groups of those with a risk score of 5 and above at baseline, showed there was a significant 
difference between groups with the general population experiencing a greater reduction in 
risk scores (p=0.03). 
 
Discussion 
Using the Checklist stimulated open discussions about SUDEP risk. The exercise has acted as 
a catalyst to improve care and outcomes in the longer term.  The value of education and 
empowerment is intuitive in all areas of clinical risk reduction and is particularly relevant in 
epilepsy.  
This is a before and after assessment of the introduction of the Checklist in the general neurology 
clinic. There may be confounders contributing to the change in risk status, as, for instance, changes 
in treatment could have reduced risk independently. Ideally, the Checklist should have been being 
validated using a randomized control approach in which controls receive no information on SUDEP 
which is currently the practice in many sites.  This could, however, be deemed non-ethical as 
withholding safety information could have implications.  Using the ID clinic as a comparison group, 
however, provides some strengths to the findings as the Checklist had long been used in this setting 
and modifiable factors were considered addressed in this population. Unlike other parts of the UK, 
Cornwall decommissioned long stay institutions and hospitals for people with ID over ten years ago. 
Most people with ID now live in bespoke placements in the community and are supported on an as 
required basis for their specific needs.  The Checklist is used regularly in this population to 
communicate and mitigate risks. Thus this population had been previously exposed to the 
‘intervention’ while the general population had not. 
 
This is not an ideal comparator especially as this group has more treatment resistance and 
multimorbidity. The two groups could be seen as separate but affiliated cohorts with some shared 
commonality such as seizures. Issues such as harmful use of alcohol, 24/7 supervision, assured 
compliance, reliable seizure feedback from care providers may be confounders.   
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The focus is on examining if the Checklist could lead to change in modifiable risk factors by 
structured communication. Thus irrespective of the nature of the groups, the study ascertains if the 
Checklist positively influenced a change in modifiable risk especially in the general population group 
when compared to the ID group. The focus is on changes within each group over a year period.   
 
Looking at the change from baseline with regard to specific factors the general population 
group showed significant reduction in the factors of seizure frequency (p = 0.019) and 
severity (p <0.001). This suggests that safety advice has possible direct implications on 
seizure factors. As seizure frequency is the single most important factor associated with 
SUDEP change would make people safer. The other factor which showed significant change 
was sleeping posture (p = 0.046). While advice was given of this risk and people appear to 
have made an effort to change their sleeping posture consciously little can be yet said of its 
utility.  
In the ID population no change in modifiable factors had been expected. This was largely 
true other than for a positive and significant association to the treatment of depression 
(p=0.046). This did not correspond to a direct change in seizure factors or overall risk.  
Even in the ID population which at baseline was thought to be ‘non-modifiable’ from a risk 
perspective had a noticeable improvement in the top 25% scores.  This highlights that 
modifiable factors such as seizure frequency often fluctuate over time requiring ongoing 
vigilance.  
There were differences between groups in terms of seizures and number of AEDs which may 
also introduce bias.  About a third of both cohorts were lost for the second assessment and 
it is unclear if the Checklist had an impact on them.  
This is one of the first attempts to measure the impact of the introduction of a safety 
Checklist in SUDEP and seizure risk management.  It would be important to evaluate the 
effectiveness of health promotion measures such as this list in other clinical settings. Our 
project also challenges views that attitudes to SUDEP cannot be altered by counselling. A 
small study in young adults had shown a cynical view from the young people [12] and it 
could be argued that a lack of structured engagement especially identifying clear areas of 
change might have been a possible reason for such an attitude.  
Implications for clinical practice 
This supports the introduction of a safety Checklist as it provides some evidence that people 
with epilepsy and their carers respond to the Checklist in a way as to seizure risk.  Creating 
such baseline scores and risk stratification for known risk factors is a first step in improving 
awareness among individuals with epilepsy and also clinicians in such settings. Having 
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ongoing risk discussions, using tools such as the Checklist, to reduce these risks where 
possible must follow to help tackle premature mortality. Further as this enables a clinician –
patient partnership it helps overcome possible hurdles for clinicians and reduces ambiguity 
which could have resulted in the lack of risk communication of risk to-date [7, 8] . 
Implications for policy 
Promoting health promotional checklists in epilepsy may reduce morbidity and mortality as 
risk factors can be modifiable and change over time and this has important public health 
implications. 
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Table 1:  Key Risk Factors of SUDEP and Seizure Safety and their description: Adapted from 
https://sudep.org/checklist  11, 12,13  
Modifiable factors are identified as (M) next to them.  
Severity of seizures (M) 
This is evidenced by an increase in the last 6 months of the  administration of rescue medication such 
as Midazolam, paramedic call outs or ED visits as recorded in clinical notes 
Compliance issues (M) 
This factor is defined by finding of variable AED hair strand levels in SUDEP group. Compliance issues 
were also assessed via patient reporting as evidenced by medical records in both groups. Adherence 
issues (including not picking up prescriptions) found as a factor across all epilepsy-related deaths as 
increasing risk by 50% 
Frequent AED changes (M) 
This is defined as where the changes of dose or medication were not following British National 
Formulary (BNF) guidance on titration in the last 6 months. 
Sub therapeutic AED levels 
Is a finding linked closely to compliance 
Alcohol problem (M) 
Is defined as where there is a clinically definable alcohol disorder as identified by the WHO ICD 10 
diagnostic Manuel. A systematic analysis of epilepsy deaths confirmed this risk factor. 
Depression treatment (M) 
This is defined as having clinical depression as per ICD 10 /DSMV and/or being on antidepressant 
medication’ as defined by BNF 4.3 and/or having therapy/counseling for depression. 
Currently it is unclear how relevant a risk or a safety factor depression or its treatment particularly 
SSRIs are. This is has not been clearly defined. 
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Presence of anxiolytic  medication (M) 
This is defined as having ‘anxiolytic medication’ as defined by BNF 4.1.2 
Currently it is unclear how relevant a risk factor this is as it has not been clearly defined.  
Night surveillance (M) 
Nocturnal Seizures were shown to have a 4 fold increased risk and accounted for 60% of all SUDEPs in 
large control study. Nocturnal surveillance thus where present is considered to be a protective factor. 
Sleeping in prone position (M) 
Independent risk factor evidenced by several studies including a systematic review. 
The prone position is defined as lying on the belly, chest, or face, with or without obstruction of the 
nose or mouth.  Sleeping in the prone position or remaining in a prone position post seizure is 
considered a risk. 
Convulsive Seizures (M) 
Combined data from the previous four case-control studies found this is the most important risk factor 
Increasing seizure frequency (M) 
Active Seizures which in the last 6 months were noted to worsen in frequency of > 25%  
Assessment for epilepsy surgery (M) 
Where available or referred to tertiary centres if eligible can have a positive impact on seizures and 
SUDEP 
Duration (>15 years) 
This has been suggested by several studies, but not after multiple logistical regression analysis for 
seizure frequency 
Early onset epilepsy 
Where the onset of epilepsy is before the age of 15 years 
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Table 2: Description of the participants and their risk factors of the Specialist General Population 
epilepsy clinic and the specialist Intellectual Disability (ID) epilepsy clinic   at baseline (number and 
percentage except where shown otherwise) 
 General (n=130) ID (n=129) P value provided where 
significant. All other 
group differences at 
baseline for variables 
were non-significant 
(p≥0.05). 
Gender    
  Male 72 (55%) 75 (58%)  
  Female 58 (45%) 54 (42%)  
    
Age (years): Mean as Standard 
Deviation (SD) 
42 (20) 37 (14)  p= 0.01 
    
Duration of epilepsy   p <0.001 
  <5 years 53 (41%) 7 (5%)  
  5-10 years 29 (22%) 1 (1%)  
  10-15 years 6 (5%) 3 (2%)  
  15+ years 42 (32%) 117 (91%)  
Unknown 0 1  
    
Generalised Epilepsy   p<0.001 
  Yes 36 (28%) 87 (68%)  
  No 93 (72%) 41 (32%)  
Unknown 1 1  
    
Presence of intellectual 
disability 
   
  Yes 0 (0%) 129 (100%)  
  No 130 (100%) 0 (0%)  
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Severity of seizures in last 3-6 
months 
   
  Increasing 43 (33%) 36 (28%)  
  Stable 61 (47%) 64 (50%)  
  Decreasing 25 (19%) 29 (22%)  
Unknown 1 0  
    
Number of Antiepileptic drugs 
(AEDs)  
 baseline: Mean (SD) 
1.4 (0.6) 2.2 (1.0) P <0.001 
Number of AEDs endpoint 
:Mean (SD) 
1.5 (0.6) 2.1 (1.0) P<0.001 
    
Compliance issues    
  Yes 15 (12%) 14 (11%)  
  No 115 (88%) 115 (89%)  
Unknown 0 0  
    
Reported alcohol problems   P =0.002 
  Yes 12 (9%) 1 (1%)  
  No 117 (91%) 128 (99%)  
Unknown 1 0  
    
 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3: Univariate analysis of change in behaviour for general population one year post baseline   
Risk factor positive 
change 
no change negative 
change 
No data p-value* 
      
Modifiable factors      
Severity of seizures 22 53 15 40 <0.001 
Number of AEDs 4 79 8 39 0.387 
Compliance issues 8 77 6 39 0.789 
Frequent AED prescribing issues 4 86 1 39 0.371 
Sub therapeutic AED levels 5 86 0 39 0.074 
Reported alcohol problem 9 78 3 40 0.149 
Treatment for depression 2 85 3 40 1.000 
Anxiolytic medication 1 87 3 39 0.617 
      
Moderate risk-modifiable factors      
No surveillance at night 9 73 9 40 1.000 
Prone position 8 77 1 44 0.046 
Failed assessment for epilepsy surgery  0 90 1 39 1.000 
      
Established risk-modifiable factor      
High seizure frequency especially 
convulsive seizures 
17 69 5 39 0.019 
      
 
 *McNemar’s test 
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Table 4: Univariate analysis of change in behaviour for ID population one year post baseline 
Risk factor Positive 
change 
No change Negative 
change 
No data p-value* 
      
Modifiable factors      
Severity of seizures 28 35 30 36 0.960 
Number of AEDs 18 64 11 36 0.683 
Compliance issues 7 83 2 37 0.182 
Frequent AED prescribing issues 6 84 3 36 0.505 
Sub therapeutic AED levels 0 90 0 39 1.000 
Reported alcohol problem 1 92 0 36 1.000 
Treatment for depression 1 83 8 37 0.046 
Anxiolytic medication 3 89 1 36 0.617 
      
Moderate risk-modifiable factors      
No surveillance at night 8 73 9 39 1.000 
Prone position 5 46 2 76 0.450 
Failed assessment for epilepsy 
surgery  
3 83 1 42 0.617 
      
Established risk-modifiable factor      
High seizure frequency especially 
convulsive seizures 
7 76 10 36 0.628 
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Table 5: Comparison of the risk score changes in modifiable factors over one year of the 
25% most risky of the two cohorts  
 
Change in risk in both groups of people having 5 or more risk factors (top 25%) 
 Baseline number of 
people with over 5 risk 
factors  
After one year  
number of people with 
over 5 risk factors 
Change  
General  (n = 91) 19 2 p<0.001 
ID (n =93) 20 6 p<0.001 
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Figure 1 Distribution of risk scores at baseline and follow-up in the general and ID clinic 
populations 
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